Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

Caroline M. Apovian, Louis J. Aronne, Daniel H. Bessesen et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 1.3K citations · Full text

Medicine, Endocrinology, Pharmacotherapy +12

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Karine Clément, Erica L T van den Akker, Jesús Argente et al. · The Lancet Diabetes & Endocrinology · 2020 · 463 citations

Medicine, Endocrinology, Pharmacology +15

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency

Tinh‐Hai Collet, B. Dubern, Jacek Mokrosiński et al. · Molecular Metabolism · 2017 · 300 citations · Full text

Life Sciences, Pharmacology, Physiology +16

Octreotide Therapy of Pediatric Hypothalamic Obesity: A Double-Blind, Placebo-Controlled Trial

Robert H. Lustig, Pamela S. Hinds, Karen Ringwald-Smith et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 296 citations · Full text

Medicine, Endocrinology, Pediatrics +17

Obesity in Patients with Craniopharyngioma: Assessment of Food Intake and Movement Counts Indicating Physical Activity

K Harz, Hermann L. Müller, E Waldeck et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 213 citations

Nursing, Nutritional Sciences, Oncology +15